Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHSE:600771'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.95 Med: 0.74 Max: 5.5
Current: 0.52
During the past 13 years, the highest Debt-to-EBITDA Ratio of GuangYuYuan Chinese Herbal Medicine Co was 5.50. The lowest was -23.95. And the median was 0.74.
SHSE:600771's Debt-to-EBITDA is ranked better than 70.71% of 676
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs SHSE:600771: 0.52
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
GuangYuYuan Chinese Herbal Medicine Co Debt-to-EBITDA Related Terms
GuangYuYuan Chinese Herbal Medicine Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuangYuYuan Chinese Herbal Medicine Co Debt-to-EBITDA Chart
GuangYuYuan Chinese Herbal Medicine Co Annual Data
SHSE:600771 vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, GuangYuYuan Chinese Herbal Medicine Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GuangYuYuan Chinese Herbal Medicine Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GuangYuYuan Chinese Herbal Medicine Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where GuangYuYuan Chinese Herbal Medicine Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) has a Debt-to-EBITDA of 0.77 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on GuangYuYuan Chinese Herbal Medicine Co. This is near median its historical median of 0.74. According to the industry distribution chart, GuangYuYuan Chinese Herbal Medicine Co ranks #198 out of 676 companies in the Drug Manufacturers industry, placing it in the top 29.3%.
Is GuangYuYuan Chinese Herbal Medicine Co's Debt-to-EBITDA too high?
GuangYuYuan Chinese Herbal Medicine Co's current Debt-to-EBITDA of 0.77 is near median its 10-year median of 0.74. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. GuangYuYuan Chinese Herbal Medicine Co's value of 0.77 is 53% below this industry median. Based on the distribution chart, GuangYuYuan Chinese Herbal Medicine Co ranks #198 out of 676 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GuangYuYuan Chinese Herbal Medicine Co has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GuangYuYuan Chinese Herbal Medicine Co's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GuangYuYuan Chinese Herbal Medicine Co ranks #198 out of 676 companies for Debt-to-EBITDA. This puts GuangYuYuan Chinese Herbal Medicine Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. GuangYuYuan Chinese Herbal Medicine Co's value of 0.77 is 53% below this benchmark. While the company's 10-year median is 0.74 vs. the industry median of 1.64, GuangYuYuan Chinese Herbal Medicine Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 676 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GuangYuYuan Chinese Herbal Medicine Co's current Debt-to-EBITDA of 0.77 is 53% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on GuangYuYuan Chinese Herbal Medicine Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GuangYuYuan Chinese Herbal Medicine Co's current Debt-to-EBITDA is 0.77, which is near median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GuangYuYuan Chinese Herbal Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥22.06, compared to a current price of ¥13.86 — trading 37.2% below its estimated fair value. The current Debt-to-EBITDA is 0.77, which is near median its 10-year median of 0.74 and 53% below the Drug Manufacturers industry median of 1.64. GuangYuYuan Chinese Herbal Medicine Co's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771), the current Debt-to-EBITDA is 0.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) Overvalued in 2026?
Based on GuruFocus' analysis, GuangYuYuan Chinese Herbal Medicine Co stock appears to be undervalued.
The current stock price of ¥13.86 is trading 37.2% below its estimated GF Value™ of ¥22.06.
GuruFocus considers GuangYuYuan Chinese Herbal Medicine Co to be Significantly Undervalued.
Key valuation signals for SHSE:600771:
Debt-to-EBITDA: 0.77 (near median its 10-year median of 0.74)
GF Value™: ¥22.06 vs. price of ¥13.86 (37.2% below fair value)
Industry Position: 53% below the Drug Manufacturers median (#198 of 676)
No single metric tells the full story. See the SHSE:600771 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GuangYuYuan Chinese Herbal Medicine Co Ltd distributes pharmaceutical products. Its products include far plate turtle age wine bottle, niuhuang qingxin pills, boutique angong niuhuang wan, modified turtle age wine, ding kundan, and many more.
58GF Score
Get the complete analysis for SHSE:600771
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600771 has been successfully added to your 
